Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
October 15, 2012 08:00 ET
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...
U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer
October 09, 2012 08:00 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
Laurantis Pharma Completes Funding Round for Research Program
September 04, 2012 07:59 ET
|
Laurantis Pharma OY
BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
U.S. Patent Office Allows Laurantis Application for Treatment of Skin Inflammation
August 01, 2012 08:00 ET
|
Laurantis Pharma Oy
TURKU, FINLAND--(Marketwire - Aug 1, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) as it pertains to the topical...
Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study
June 28, 2012 10:03 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Jun 28, 2012) - Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to...
Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone
March 06, 2012 14:30 ET
|
Laurantis Pharma OY
VENTURA, CA--(Marketwire - Mar 6, 2012) - Lymphedema Awareness Day was established to support the needs of patients with lymphedema and to raise awareness for the need to develop new treatment...